Partner Headlines - BMRN

  1. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD
  2. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus
  3. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing ...

    Benzinga
  4. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD
  5. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD
  6. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial ...

    Benzinga
  7. BioMarin, Intercept hit by FDA

    IBD
  8. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD
  9. BioMarin Announces That FDA Has Advised it Will Not Take Action ...

    Benzinga
  10. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' ...

    GuruFocus
  11. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD
  12. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's ...

    Benzinga
  13. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD
  14. BIOMARIN PHARMA

    IBD
  15. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD
  16. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga
  17. Morning Market Losers

    Benzinga
  18. Benzinga's Top #PreMarket Losers

    Benzinga
  19. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  20. Benzinga's Top Initiations

    Benzinga
  21. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  22. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD
  23. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD
  24. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide ...

    Benzinga
  25. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD
  26. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise ...

    Benzinga
  27. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical ...

    Benzinga
  28. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD
  29. Benzinga's Top #PreMarket Losers

    Benzinga
  30. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  31. BioMarin Announces Two Oral and 19 Poster Presentations at the ...

    Benzinga
  32. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  33. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  34. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  35. BioMarin Receives Rare Pediatric Disease Designation From FDA ...

    Benzinga
  36. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  37. 2 DMD drugs make progress

    IBD
  38. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  39. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  40. Benzinga's Volume Movers

    Benzinga
  41. Benzinga's Top Downgrades

    Benzinga
  42. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  43. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  44. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  45. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  46. Benzinga's Volume Movers

    Benzinga
  47. Morning Market Gainers

    Benzinga
  48. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  49. Benzinga's Top #PreMarket Gainers

    Benzinga
  50. BIOMARIN PHARMA

    IBD
  51. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  52. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  53. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  54. Benzinga's Top Initiations

    Benzinga
  55. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  56. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  57. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  58. BIOMARIN PHARMA

    IBD
  59. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  60. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  61. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  62. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  63. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  64. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  65. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  66. BIOMARIN PHARMA

    IBD
  67. State Of The Union Lights Up Biotech

    Benzinga
  68. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  69. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  70. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  71. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  72. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  73. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  74. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  75. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  76. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  77. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  78. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  79. BioMarin buying Prosensa

    IBD
  80. Trio Of Major Deals Disclosed

    IBD
  81. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  82. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  83. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  84. Benzinga's Volume Movers

    Benzinga
  85. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  86. Stocks Hitting 52-Week Highs

    Benzinga
  87. Morning Market Movers

    Benzinga
  88. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  89. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  90. Benzinga's Top #PreMarket Gainers

    Benzinga
  91. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  92. Stocks Hitting 52-Week Highs

    Benzinga
  93. Benzinga's Top Upgrades

    Benzinga
  94. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  95. BioMarin Weathers The Storm

    Benzinga
  96. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  97. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  98. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  99. Benzinga's Top Upgrades

    Benzinga
  100. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
Trading Center